Global Pancreatic Cancer Drugs Market Size | COVID-19 Impact Analysis | Forecast to 2026
The global pancreatic cancer drugs market has significant opportunity owing to the emerging drugs in
the pipeline for the treatment of pancreatic cancer. Several immunotherapies
and targeted therapies are under the pipeline. Immunotherapies are mostly in
trial stages and less is available on the market for the treatment of
pancreatic cancer. Several immunotherapy options are available on the market
for the treatment of other cancer types, including breast cancer and some are
under trials for pancreatic cancer. In 2017, the US FDA approved pembrolizumab
(Keytruda), an immunotherapy to treat pancreatic cancer patients with certain
genetic mutations and is manufactured by Merck.
To Request a Sample of our Report on Global Pancreatic
Cancer Drugs Market: https://www.omrglobal.com/request-sample/pancreatic-cancer-drugs-market
The drug may be an alternative for a small percentage of people
suffering from unresectable pancreatic cancer. It works by blocking the ability
of cancer cells’ to avoid an immune attack. Cancers with high microsatellite
instability (MSI) have been demonstrated to be mainly prone to treatment with
Keytruda. High MSI can be found in pancreatic cancers, however, it is not
common. Targeted therapies that are available for the treatment of pancreatic
cancers include Erlotinib and Larotrectinib (Vitrakvi). The US FDA approved
Erlotinib for patients living with advanced pancreatic cancer along with the
chemotherapy drug Gemzar (gemcitabine).
Erlotinib is used to block the epidermal growth factor receptor
(EGFR) effect. EGFR is a protein that can become abnormal and support the
growth and spread of cancer. One of the major instance for targeted therapy
under trial is Lupin’s MEK inhibitor compound (LNP3794). In September 2019,
Boehringer Ingelheim and Lupin Ltd. declared a licensing, development, and
commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as an
effective targeted therapy for patients suffering from difficult-to-treat
cancers. This collaboration intends for the development of Lupin’s lead MEK
inhibitor compound along with one of innovative KRAS inhibitors of Boehringer
Ingelheim for patients suffering from lung and gastrointestinal cancers
harboring a comprehensive spectrum of oncogenic KRAS mutations.
KRAS mutations occur in one in seven of entire human metastatic
cancers which makes it the most often mutated cancer-causing gene, with
mutation rates of over 90% in pancreatic cancers, over 40% in colorectal
cancers and over 30% in lung adenocarcinomas. Lupin’s MEK Inhibitor program has
cleared early clinical stages. The emerging trials on such kinds of novel drugs
will likely offer an opportunity for more reliable, accurate, and potential
treatment for pancreatic cancer. This, in turn, is expected to accelerate the
growth of the global pancreatic cancer drugs market.
(Get 15% Discount on Buying this Report)
A full
Report of Global Pancreatic Cancer Drugs Market is Available at: https://www.omrglobal.com/industry-reports/pancreatic-cancer-drugs-market
Global Pancreatic Cancer Drugs Market- Segmentation
By Cancer Type
- Exocrine
- Endocrine
By Treatment Type
- Chemotherapy Drugs
- Targeted Therapy Drugs
- Immunotherapy Drugs
Global Pancreatic Cancer Drugs Market– Segment by Region
North America
- US
- Canada
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Latin America
- The Middle East and Africa
Company Profiles
·
AbbVie
Inc.
·
Amgen
Inc.
·
AstraZeneca
plc
·
Bayer
AG
·
Boehringer
Ingelheim GmbH
·
Bristol-Myers
Squibb Co.
·
Cipla
Ltd.
·
Clovis
Oncology, Inc.
·
Eli
Lilly and Co.
·
F.
Hoffmann-La Roche AG
·
GlaxoSmithKline
plc
·
Kura
Oncology, Inc.
·
Lupin
Ltd.
·
Merck
& Co., Inc.
·
Novartis
International AG
·
Pfizer
Inc.
·
PharmaCyte
Biotech, Inc.
·
Sun
Pharmaceutical Industries Ltd.
·
Teva
Pharmaceutical Industries Ltd.
Reasons to Buy From
us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More
Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/pancreatic-cancer-drugs-market
Orion Market Research (OMR) is a market
research and consulting company known for its crisp and concise reports. The
company is equipped with an experienced team of analysts and consultants. OMR
offers quality syndicated research reports, customized research reports,
consulting and other research-based services.
For More Information, Visit Orion Market Research
Media Contact:
Company Name: Orion Market
Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment